Bristol Myers Squibb's CAMZYOS Approved for Expanded Indication by FDA

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval covers both adult and pediatric patients weighing 30 kg and above, aiming to improve functional capacity and symptoms.